Efficient Delivery of Proteins into Living Cells
BioPORTER Protein Delivery Reagent from AMSBIO is a unique lipid formulation that allows direct translocation of proteins into living cells.
BioPORTER is the first and only lipid-based protein delivery system that efficiently transports proteins into living cells. Comprising a unique cationic lipid mixture that interacts non-covalently with the protein, BioPORTER creates a protective vehicle for immediate protein delivery. BioPORTER makes studying protein functionality faster and easier than ever before by bypassing the traditional DNA transfection, transcription, and protein translation processes.
After capturing the protein, the reagent transports the lipid protein complex into the target cell. The delivered proteins retain their structure and function while leaving the transduced cells unharmed.
Because of its simple delivery mechanism and because there’s no fusion partner or covalent bond formation, BioPORTER can efficiently deliver functionally active proteins into a wide range of cell types. The reagent is especially useful when studying protein function in cells that are difficult to transfect using traditional DNA transfection reagents.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...